Physician profile
Michael Edward Gray
NPI 1700442407
$1,258.42
in general payments reported to CMS, 2019-2025
18 companies · $844 in 2025
The $844 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $129 · 2023: $80.64 · 2024: $204 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $447.44 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abiomed | $123.46 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $111.88 | 2022-2025 | |
| Corcept Therapeutics | $102.12 | 2025 | Korlym |
| Gilead Sciences, INC. | $80.64 | 2023 | Epclusa |
| Amgen INC. | $64.51 | 2022-2025 | Krystexxa |
| Boston Scientific Corporation | $49.09 | 2025 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $46.61 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $42.02 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $31.25 | 2025 | Voquezna |
| Lilly USA, LLC | $29.17 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $24.63 | 2025 | |
| Astellas Pharma US INC | $20.33 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $19.80 | 2025 | Rexulti |
| Springworks Therapeutics, INC. | $18.79 | 2025 | Gomekli |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $17.46 | 2025 | Fluad, Flucelvax |
| Madrigal Pharmaceuticals | $14.78 | 2025 | Rezdiffra |
| Dexcom, INC. | $14.44 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.